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Sensory deficits have been documented in Parkinson’s disease, in particular within the visual domain. However,
ageing factors related to the brain and to neural and non-neural ocular structures could explain some of the
previously reported results, in particular the claimed impairment within the koniocellular pathway.This study
addressed visual impairment attributable to the magno- (luminance), parvo- (red–green) and koniocellular
(blue–yellow) pathways in a population of Parkinson’s disease patients. To avoid potentially confounding
factors, all subjects underwent a full neurophthalmological assessment which led to exclusion of subjects
with increased intraocular pressure, diabetes even in the absence of retinopathy, and ocular abnormalities
(from a total of 72 patients’ eyes, 12 were excluded). Both parvo- and koniocellular pathways were studied by
means of contrast sensitivity (CS) measurements along protan, tritan and deutan axes and also by fitting
chromatic discrimination ellipses using eight measured contrast axes. Magnocellular function was assessed,
using stimuli that induce a frequency doubling illusion, in 17 locations in the fovea and periphery. Achromatic
(luminancemodulation) thresholds were significantly higher in Parkinson’s disease both in foveal and peripheral
locations. A significant impairment was observed along protan and deutan axes, but only marginally along the
tritan axis. These results were corroborated by a significant elongation of chromatic discrimination ellipses in
our Parkinson’s disease group. Correlation analysis showed that achromatic and chromatic CS measures were
independent, which implies that multiple visual pathways are affected independently in Parkinson’s disease.
Magnocellular impairment was significantly correlated with age and disease stage, in contrast to the measured
chromatic deficits. We conclude that in Parkinson’s disease, independent damage occurs in the early magno-
and parvocellular pathways. Furthermore, traditional koniocellular probing strategies in Parkinson’s disease
may be confounded by ageing factors, which may reconcile the previously reported controversial findings
concerning chromatic impairment in Parkinson’s disease.
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Introduction
The nature of previously described visual deficits in
Parkinson’s disease has been questioned mainly on the
ground that the reported deficits do not reflect a sensory
deficit, but rather confounding cognitive factors (Crucian
and Okun, 2003; Geldmacher, 2003). Moreover, many
previous studies have probed contrast sensitivity (CS)
using clinical semi-quantitative tests such as the Lanthony
D15, Farnsworth–Munsell 100-Hue, Pelli-Robson test charts
and Vistech tables (Regan and Maxner, 1987; Buttner et al.,
1995; Pieri et al., 2000; Diederich et al., 2002). One should,
however, emphasize the important previous work using
quantitative psychophysical methods in Parkinson’s disease
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(Bodis-Wollner et al., 1987; Bodis-Wollner and Regan, 1991;
Harris 1998; Regan et al., 1998; Bodis-Wollner, 2003). It is
also important to measure CS with such precise psychophys-
ical methods. It is worth emphasizing that most of the clinical
tests do not allow for extraction of subject reliability para-
meters and provide limited quantification power. New
psychophysical methodologies are less prone to artefacts
than classical clinical methods that assess chromatic and
achromatic contrast discrimination. In fact, Regan et al.
(1994) have previously analysed the potential between com-
puterized approaches and current clinical tests. In general,
clinical tests, such as Farnsworth–Munsell 100-Hue or Farns-
worth D15 test, are much less sensitive and less reproduci-
ble—which we have also confirmed before—in comparison
with techniques that allow for very fine contrast adjustments
using randomly interleaved staircases (Castelo-Branco et al.,
2004; Campos et al., 2005). Roth and Lanthony (1999)
provide a good description of the limitations of
Farnsworth–Munsell 100-Hue test. Farnsworth himself did
consider that 30% changes in test-retest could occur, which
was confirmed by Birch et al. (1998). Reeves et al. (1989) had,
in fact, documented that a difference in global score would
only be significant if the difference is >50. This led Roth and
Lanthony (1999) to conclude that the Farnsworth-100 test is
just a semi-quantitative evaluation test. Accordingly, it has
been postulated that commonly used clinical colour tests are
not suitable for the early detection or monitoring of treat-
ments in Parkinson’s disease (Birch et al., 1998). Furthermore,
it is also important to use psychophysical tests that do not rely
on higher level visuospatial abilities, such as orientation dis-
crimination (Regan and Maxner, 1987; Bulens et al., 1988). In
addition, ageing factors related to the brain, and also to the
retina and other ocular structures (Wyszecki and Stiles, 1982;
Pokorny et al., 1987; for reviews see Werner et al., 1990;
Packer and Williams, 2003) could explain some of the
previously described results, in particular the widely reported
deficits in the koniocellular pathway (for a review see
Haug et al., 1994, 1995; Harris 1998; Pieri et al., 2000, but
see Birch et al., 1998; Regan et al., 1998). Common age-related
and progressive ocular diseases in older adults such as catar-
act, age-related maculopathy, glaucoma, and diabetic retino-
pathy are often associated with sensory deficits (Jackson and
Owsley, 2003; Castelo-Branco et al., 2004; for a comprehens-
ive review of the literature see Roth and Lanthony, 1999). In
spite of such potentially confounding factors, there is strong
evidence that spatiotemporal CS deficits do occur in Parkin-
son’s disease (Bodis-Wollner and Yahr, 1978; Marx et al.,
1986; Skrandies and Gottlob, 1986; Bodis-Wollner et al.,
1987; Regan and Maxner, 1987; Mestre et al., 1990a, b;
Bodis-Wollner and Regan, 1991; Harris et al., 1992; Delalande
et al., 1996; Mestre et al., 1996; Tebartz van Elst et al., 1997;
for reviews see Bodis-Wollner, 1990, 2003; Harris 1998;
Langheinrich et al., 2000; Pieri et al., 2000; Diederich et al.,
2002).
In the current study we aimed to analyse visual perform-
ance within multiple visual channels, both in the fovea and the
periphery, using tests that tackle the function of
those pathways in an independent manner. This strategy
allowed for the analysis and comparison of relative patterns
of damage within magno-, parvo- and koniocellular pathways
in Parkinson’s disease. To account for the above-mentioned
methodological problems, we used age-matched populations
and conservative exclusion criteria (e.g. diabetes in pre-
retinopathy stage, ocular hypertension in pre-glaucomatous
stage, fundus signs of age-related macular degeneration). To
study chromatic CS performance, we adopted a new
methodological approach, based on the seminal work of
Regan et al. (1994), with randomly interleaved psychophysical
staircases with spatial and luminance noise (see Castelo-
Branco et al., 2004; Campos et al., 2005). Stimulus parameters
were adjusted along colour modulation axes in order to
separate dysfunction within parvo- and koniocellular
systems. This strategy allowed independent and non-biased
assessment of the relative damage of parvo- and koniocellular
pathways.
The parvo- and koniocellular isolating strategy relied
on chromatic properties and not on spatiotemporal criteria.
The choice was based on neurophysiological and lesion
studies in primates, which show that chromatic criteria are
by far the best to provide isolation (Lee, 1996). Indeed
isolation based on spatial vision often fails, and vernier
acuity may be preserved even after wholesale destruction of
P-cells, suggesting incomplete isolation (Lynch et al., 1992).
This led us to choose chromatic properties as the isolating
criteria.
To probe the magnocellular pathway (M/Y) at early ret-
inotopic levels we choose a CS task that uses a sinusoidal
grating stimulus at high temporal and low spatial frequency.
This spatiotemporal profile of the stimulus is, in general,
appropriate to activate the M/Y pathway but may not be
sufficient to isolate its function, unless one uses stimulus
parameters such that an illusory duplication of number of
stripes is perceived (Kelly, 1981). This frequency-doubling
(FD) illusion reflects a non-linearity that resembles the
response properties of the M/Y system (Shapley and Victor,
1980). Between 5 and 20% of LGN M cells respond with
this non-linear Y-type response (Kaplan and Shapley, 1982;
Derrington and Lennie, 1984; Purpura et al., 1988, 1990).
Neurophysiological evidence has also shown that these stimuli
differentially activate magno neurons (Derrington and
Lennie, 1984; Merigan and Maunsell, 1993; Lee, 1996).
Given the low percentage of responding M/Y neurons, this
approach provides functional isolation and improves the like-
lihood of detecting early level impairment due to reduced
compensation by functional redundancy mechanisms.
The value of FD stimuli to assess retinotopic magnocellular
damage as early as the retina stage has already been applied in
glaucoma, because large retinal ganglion cell fibres (most of
which are of magnocellular origin) are preferentially affected
in this disease (Quigley et al., 1987, 1988; Maddess and Henry,
1992; Glovinsky et al., 1993; Merigan and Maunsell, 1993;
Johnson and Samuels, 1997; Maddess et al., 1999;
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Cello et al., 2000; Landers et al., 2000; Trible et al., 2000;
Paczka et al., 2001; McKendrick et al., 2003; for a review
see Shabana et al., 2003). Based on this evidence, we adopted
the FD paradigm to study early magnocellular function in
Parkinson’s disease.
Methods
Patient selection and classification
All Parkinson’s disease patients were recruited from the Neurology
Department of Coimbra University Hospital. Control subjects were
patients’ spouses, age-matched hospital or university staff, or relat-
ives, with normal or corrected to normal refraction. Informed
consent was obtained from all participants, and the study was con-
ducted in accordance with the tenets of the Declaration of Helsinki,
and the guidelines of our local ethics committee were followed. Both
groups underwent full ophthalmological examination by two oph-
thalmologists (P. Faria, L. Duarte). This examination consisted of
best-corrected visual acuity (VA; Snellen chart), slit lamp examina-
tion of anterior chamber, IOP measurement (Goldman applanation
tonometer), angle and fundus examination (Goldman lens), cataract
grading by the Lens Opacities Classification System II (LOCS) and
the assessment of subjective visual complaints. Neurological exam-
ination was performed in our Neurology Department by two of the
authors (A. Freire and C. Janua´rio). Dementia was excluded by
analysis of Mini Mental State Examination scores (Portuguese-
adapted version by Guerreiro et al., 1994 following Folstein et al.,
1975). For exclusion of depression, the Hamilton Depression Rating
Scale 17 (cut-off 14) was used.
Parkinson’s disease patients were classified in stages of the
modified Hoehn and Yahr clinical scale [1.9 6 0.5 (mean 6 SD)
for both subsets of chromatic and achromatic testing]. The motor
Unified Parkinson’s Disease Rating Scale (UPDRS) was also applied
[UPDRS motor score, 25.06 8.4 (chromatic testing) and 23.96 9.3
(achromatic testing)].
The following exclusion criteria were applied: neurological/
psychiatric conditions other than Parkinson’s disease (see above),
diabetes even in the absence of retinopathy, increased intraocular
pressure even in the absence of glaucoma, congenital colour vision
disorders, VA < 0.6 , high ammetropy (sphere dpt > 4 and cylinder
dpt > 2), cataract (LOCS  2) and other ophthalmological diseases.
From a total of 36 Parkinson’s disease patients we excluded 6
(3 with diabetes even in absence of retinopathy, 2 with glaucoma
and 1 patient with high ocular hypertension). The final subset
of Parkinson’s disease patients (14 male and 16 female) had a
mean illness duration of 4.6 6 3.0 years. Our patient and control
(32; 13 male, 19 female) populations had age distributions that
were not significantly different under all testing procedures (chro-
matic assessment: control subjects: mean age = 57.9 6 7.6 years;
Parkinson’s disease: 61.1 6 10.4 years; achromatic testing: control
subjects: 58.5 6 9.5 years; Parkinson’s disease: 60.0 6 10.8 years).
Mean education level was similar across groups, and was not signi-
ficantly correlated with sensory performance. Ten Parkinson’s
disease patients were newly diagnosed and were tested free
from therapy. The others were receiving conventional levodopa
therapy (mean dose of L-dopa: 544 6 238 mg daily; other agonists:
7 patients with bromocriptine, 7.5 mg; 6 patients with
ropinirole, 3.5 6 0.84 mg). The medicated patients were all tested
in the best-on state.
Psychophysical techniques to address the
function of the parvo- and koniocellular
pathways
We have probed the parvo- and koniocellular pathways in
Parkinson’s disease using a computer controlled psychophysical
method developed by Regan et al. (1994) and taken from the
Cambridge Colour Test [Cambridge Research Systems (CRS),
Rochester, UK]. This technique uses a luminance noise strategy
that forces the subject to rely exclusively on colour cues to identify
the position of a gap in a Landolt-like C-shaped ring (see Fig. 1 top
inset; gap size: 1.6, outer diameter: 7.6, inner diameter: 3.81,
viewing distance: 1.8 m). Implementation and calibration proced-
ures were performed with software and hardware provided by CRS
(Minolta colorimeter; calibration software and CRS/VSG 2/5 graph-
ics card, with 15-bit contrast resolution per pixel). Stimuli were
displayed on a 21 inch monitor (GDM-F520; Sony, Tokyo, Japan)
that was gamma-corrected.
The Parkinson’s disease population of this study was probed
monocularly for chromatic pathways (n = 30 patients eyes; n = 33
age-matched control eyes). The tested eye was chosen in a pseudo-
random manner. All participants viewed with refraction corrected
for viewing distance a screen with a pattern of circles of various
sizes and luminance with superimposed chromatic contrast defining
the C-ring. The viewing conditions were such that of all areas it was
the macular area of the retina that the Parkinson’s disease patients
had to consider to perform chromatic comparisons.
Given the subjects’ average age, and to exclude confounding
factors such as motor errors, the experimenter (F. S. Regateiro or
V. Forjaz) recorded subjects’ oral responses using a 4-button
response box. To further emphasize accuracy versus speed in the
measurement of psychophysical responses, subjects were instructed
that they had up to 20 s to report their decision. The subject had to
indicate one out of four possible gap positions (bottom, top, left and
right) of the Landolt C stimulus. Luminance and size variation of
stimulus patches (see Fig. 1, top inset) forced the subject to use
specific colour cues, since he/she could not use spatial or luminance
cues to infer the embedded shape. These patches were randomly
assigned six different luminance noise levels (8, 10, 12, 14, 16 and
18 cd/m2; see also Fig. 1 top inset, which illustrates the patches
in different shades of grey). A minimum excursion of 0.002 units in
CIE 1976 u0 v0 colour space was then superimposed on such noise
levels, to define the chromatic shape.
The chromaticity of the Landolt C shape was adjusted according
to a staircase procedure (see below). Quantitative adjustment in
terms of modulation of chromatic contrast allowed for isolation
of cone or colour-opponent specific responses in CIE 1976 (u0 v0)
colour space (see Fig. 3A). Chromatic performance along the classical
cone axes (protan, deutan and tritan labels in Fig. 3B) were explored
first: psychophysical thresholds were obtained with algorithms
implementing three independent random staircases, from the
Trivector version of the test, which ensured unbiased measurement
of thresholds across the three main chromatic axes.
Chromatic discrimination ellipses (‘confusion areas’, which rep-
resent regions in colour space that look identical to the subject) were
fitted along eight symmetrical colour vectors (Fig. 1). Quantification
of major and minor ellipse axes and orientation, allowed for com-
parison of relative damage of red–green and blue–yellow pathways.
The eight colour vectors that were used to measure chromatic
discrimination ellipses were modulated in an interleaved manner,
with independent random staircases running against a neutral
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background. Neutral background coordinates (CIE 1976 u0, v0
coordinates are shown, respectively): 0.1977, 0.4689; minimum
excursion: 0.002 unit’s u0 v0; protan confusion (copunctal) point:
0.678, 0.501; deutan confusion (copunctal) point:1.217, 0.782; and
tritan confusion (copunctal) point: 0.257, 0.0. Maximum excursion
for trivector test: 0.1100 units (Fig. 3A). This strategy allowed testing
all colour axes simultaneously, which made comparisons concerning
relative damage of chromatic pathways more reliable. On each axis,
Fig. 1 Top inset: schematic illustration of the luminance noise stimulus and superimposed chromatic target (Landolt C shape, coloured in
red). Representative examples of chromatic discrimination ellipses (raw discrimination vectors and fitted ellipses) in Parkinson’s disease,
over Stages 1–3 of the modified Hoehn and Yahr clinical scale (motor UPDRS: B, 11; C, 13; D, 18; E, 28; F, 40). Solid straight lines:
eight measured colour vectors. Curved solid line: fitted ellipse. Colour rendering (which is only approximate in the printed version) is based
on the IEC1996 2.1 standard, with the white point set to the white point of the test and the monitor gamut set to the gamut of our
Trinitron monitor. Parameters extracted from fitted ellipses were as follows (length, axis ratio and angle, respectively): (A) 0.0116, 1.316,
92; (B) 0.0184, 1.439, 97; (C) 0.0147, 1.594, 65.5; (D) 0.0382, 2.334, 73.6; (E) 0.0565, 2.673, 112, 3; (F) 0.0295, 1.636, 71.5.
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the separation between the background and target chromaticities was
initially large, and was decreased after each correct response on that
axis and increased after each error. Since the tests were measuring
multiple colour axes randomly (independent interleaved staircases),
and since there was no fixed order, attentional biases could be pre-
vented. The test terminated after 11 reversals of each of the three
individual staircases; and the mean of the last seven reversals was
taken as the threshold estimate for a given confusion line. The step
size is computed in units of the CIE 1976 uniform chromaticity space
and is a function of the number of reversals completed, and of the
separation of test and background chromaticities. Small subsets of
trials, randomly intermixed with the test trials, were used as control
trials to detect malingering and to provide the subject clear cases
when he or she is near threshold.
The ellipses fitting method which was developed by Regan et al.
(1994), produces an ellipse that is centred on the neutral back-
ground; and is obtained by minimizing the sum of squares of the
log distances between the ellipse and the fitted point, which is a
geometric solution for producing discrimination ellipses. The per-
formance varies inversely with the ellipse length. Our four alternative
spatial forced-choice strategy allowed the extraction of the following
quantitative parameters: confusion vector length, ellipse length, axis
ratio and angle. The ellipse length helps in quantifying the magnitude
of chromatic CS deficit, the axis ratio estimates the specificity of
damage and the angle provides an indication of the most affected
type of chromatic pathway.
Psychophysical techniques to address the
function of the M/Y pathway
The spatiotemporal profile of the sinusoidal grating FD stimulus was
optimized to activate the M/Y pathway. To measure luminance
modulation sensitivities, stimuli were generated directly from
CRS/VSG 2/5 graphics card (with 15-bit contrast resolution per
pixel) using CRS object animation library, (see McKendrick et al.,
2003; Silva et al., 2004). FD stimuli were displayed on a gamma-
corrected 21 inch colour Trinitron GDM-F520 monitor (frame rate
100 Hz). Each stimulus was a 10 · 10 patch of 0.25 c.p.d. (cycles
per degree) sinusoidal grating vertically oriented, undergoing 25 Hz
counter phase flicker. Mean background luminance was 61.7 cd/m2.
Stimuli were randomly presented, in two zones (see top inset of
Fig. 4): zone 1, which contains a foveal circular stimulus with
5 radius; zone 2, with 16 peripheral square stimuli between
5 and 20 eccentricity. This perimetry field analysed 17 localizations
to mimic as closely as possible the standard strategy of Humphrey
FDT (C-20).
Luminance contrast or modulation was expressed according to
the Michelson formula:
Luminance contrast (%) = 100 · (Lmax  Lmin)/(Lmax + Lmin).
An adaptive logarithmic staircase strategy from CRS object anima-
tion library was used to obtain luminance contrast thresholds. The
value to be used for a given trial was calculated using the previous
trials value plus or minus the step size in dB. The initial step size used
was 3 dB. Staircases were run for a total of four reversals, with the
contrast at the final two reversals being averaged to obtain the
threshold estimate.
FD perimetry was done in a monocular way for both eyes in
21 Parkinson’s disease patients. The first eye tested was chosen
in a random manner. We did not find any significant differences
in performance between the two eyes, and we therefore pooled these
data. The stimulus disappeared upon a button press and its max-
imum duration was 400 ms; the interstimulus duration was 250 ms.
Subjects were instructed to report the presence of ‘flickering striped’
targets and the experimenter (M. F. Silva) converted the subjects’ oral
response into a button response (4-button box). Subjects wore, when
necessary, a correction appropriate for the 36 cm viewing distance.
Participants’ reliability was evaluated by intermittently including
false positive and negative ‘catch trials’. We excluded all results
with false positive and false negative errors 33%.
A parallel set of control experiments in normal subjects (n = 100
eyes; n = 48; n = 81; n = 30 and n = 15 for different test configurations
spanning at least 17 visual locations) was also performed. This study
showed that at the tested spatiotemporal frequencies of our achro-
matic test, CS thresholds are much better (<6% in most locations)
than CS thresholds used at higher frequencies that are less optimal for
the magnocellular system (>25% for P-biased stimuli).
Data analysis
Mann–Whitney U-tests were used to compare chromatic and
achromatic (luminance modulation) performance between the
two groups (normal and Parkinson’s disease), given the lack of
data homoscedascity.
Statistical independence was analysed using standard correlation
methods (Han et al., 2004). If two measures are statistically uncor-
related (using appropriate testing criteria) they must have a different
neural source or mechanism, as explained and explored by Han et al.
(2004). It is important to note that partial correlation models are
essential if multiple parameters show correlations that are signific-
antly different from 0 (Castelo-Branco et al., 2004; Campos et al.,
2005). Independence was measured in terms of cross-sectional per-
formance and not in terms of time course. Given the data distribution
we used Spearman rank correlations (Siegel and Castellan, 1988).
Results
Assessment of parvocellular and
koniocellular damage
In order to isolate relative damage of different chromatic
pathways we measured contrast thresholds not only along
the three main colour axes that isolate cone function, (protan,
deutan and tritan) but also along eight evenly oriented vectors
that help define discrimination ellipses (see Methods). This
novel approach in Parkinson’s disease allows to fit chromatic
‘confusion areas’ (ellipses) to individual data, and to estimate
in an unbiased way relative damage across chromatic chan-
nels. The measured length and orientation of ellipses’ axes can
be used to compare damage along koniocellular (blue–yellow
opponent channel) and parvocellular pathways (red–green
opponent channel).
Representative examples of chromatic discrimination ellip-
ses are shown in Fig. 1, both for control and Parkinson’s
disease patients in different stages of the motor UPDRS
and the modified Hoehn and Yahr clinical scale (seeMethods
and Fig. 1 legend). It is worth emphasizing that ellipses have
variable length and orientation in the Parkinson’s disease
examples, suggesting evidence for heterogeneous patterns
of damage. This was further confirmed by testing homogen-
eity of variances in the Parkinson’s disease group. The latter
showed significantly increased variability (F-test, P < 0.001 for
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all parameter comparisons). Note that one of the patients in
Stage 1, shown in Fig. 1, had nearly normal performance, and
that all patients above Stage 1.5 showed increased length of
both minor and major axes, as compared to a representative
normal control.
Chromatic damage was confirmed by statistical analysis of
ellipses’ main parameters (Fig. 2). We found a significant
elongation of ellipses’ length (Fig. 2A, Mann–Whitney,
P < 0.0001). In contrast, axis ratio (a measure of specificity
of damage) was not significantly different from the control
population (Fig. 2B, Mann–Whitney, n.s.), indicating damage
across both parvo- and koniocellular chromatic pathways.
This finding is further substantiated by analysis of the relative
distribution of ellipses’ orientation (pie charts in Fig. 2C). In
our Parkinson’s disease group there was a wider range of
angle distributions, suggesting the absence of a specific axis
of damage. It is worth pointing out that a subgroup of
Parkinson’s disease patients showed protan or deutan-like
angles close to 0–30 (the values of 150–180 are actually
mirror symmetric).
In order to further investigate whether or not patterns of
damage are different along axes that isolate specific cone
pathways (see Fig. 3A), we independently analysed perform-
ance for protan, deutan and tritan colour axes. We found
significant impairment of chromatic sensitivity in Parkinson’s
disease, in particular along the protan and deutan confusion
lines (Mann–Whitney: P = 0.0003 for the protan axis, and
0.0021 for the deutan axis, P = 0.0591 for the tritan axis, which
is only close to marginal significance; see Fig. 3B).
We found no significant worsening of performance (no
fatigue) or learning effects when Parkinson’s disease patients
moved from the trivector version of the test to the ellipse
method. In another set of control experiments, designed to
Fig. 2 (A) Length of discrimination ellipses is significantly different
between control and Parkinson’s disease groups (P < 0.0001,
Mann–Whitney). (B) Axis ratios of discrimination ellipses
are not significantly different from the control group (n.s.,
Mann–Whitney). (C) Pie chart distributions of discrimination
ellipse angles (in degrees) across the two groups.
Fig. 3 (A) Confusion vectors (in CIE 1976 u0 v0 colour space)
along which the data shown in B were collected. P, protan; D,
deutan and T, tritan axes. (B) Lengths of protan, deutan and tritan
vectors are significantly different between control and Parkinson’s
disease groups (see text for details).
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verify whether results were similar under blue cone (pregan-
glionic) adaptation conditions (Shevell, 2003) we tested chro-
matic performance in seven Parkinson’s disease patients.
Ellipses were larger than for control subjects, but this increase
was proportional to the baseline impairment.
No correlations were found between age and chromatic
performance (Spearman’s rank correlation, P  0.05 for all
measures). More importantly, no significant correlation was
found between the duration of disease and the chromatic
measured parameters. Interestingly, also no significant
correlation was found between motor UPDRS scale and psy-
chophysical performance, as measured by Spearman’s rank
correlation coefficients.
The effect of dopaminergic medication was analysed using
non-parametric statistics, and no significant correlations were
found between L-dopa and trivector measured parameters, as
well as with the ellipse measured parameters.
Perimetric assessment of magnocellular
function
Concerning perimetric achromatic CS (Fig. 4), measured with
a stimulus which isolates theM/Y pathway (FD, seeMethods),
we found significant impairment in Parkinson’s disease
patients both in the fovea and in the periphery (Foveal
Index Measure, Mann–Whitney: P = 0.029; Peripheral
Index Measure which averages the 16 peripheral locations,
P = 0.012; see Fig. 5A). CS was significantly less homogeneous
in Parkinson’s disease than for control subjects [F-test across
quadrants: superior temporal field (ST), inferior nasal field
(IN), inferior temporal field (IT), superior nasal field (SN),
P  0.0001 for all comparisons]. Threshold comparisons
remained significant even when the analysis was performed
for each visual field quadrant, except for the IN quadrant
(Fig. 5B; Mann–Whitney tests: ST, P = 0.037; SN, P = 0.016;
IN, P = 0.082 n.s.; IT, P = 0.0030). This is a conservative
statistical approach, since it does not take into account
that multiple locations were measured in each quadrant.
In contrast to our findings for the chromatic tests, psycho-
physical performance for the achromatic test showed a sig-
nificant correlation with age in the Parkinson’s disease group
(Control group, n.s. for all correlations; Parkinson’s disease
group: Foveal Index Measure, r = 0.47, P = 0.0024; Peripheral
Index Measure, r = 0.49, P = 0.0017). These effects in the
Parkinson’s disease group remained significant even when
analysis was split according to visual quadrants (ST:
r = 0.40, P = 0.0106; SN: r = 0.44, P = 0.0046; IN: r = 0.35,
P = 0.0233; IT: r = 0.41, P = 0.0085; in the Parkinson’s disease
group). This was corroborated by correlation analyses
between disease duration and achromatic parameters: Foveal
Index Measure, r = 0.49, P = 0.0016; Peripheral Index Meas-
ure, r= 0.599,P= 0.0001; visual quadrants, r= 0.45, P= 0.0038
(ST); r = 0.54, P = 0.0006 (SN); r = 0.66, P < 0.0001 (IN);
r = 0.57, P = 0.0003 (IT). We then computed correlations
between modified Hoehn and Yahr stage (for UPDRS
correlations see below) and achromatic psychophysical
thresholds. We found that all correlations were significant
(Foveal Index Measure: r = 0.41, P = 0.0201; Peripheral
IndexMeasure: r = 0.38, P = 0.0304). Further analysis revealed
that nasal visual quadrants were themost significantly affected
by stage (ST: r = 0.27 n.s., P = 0.126; IT: r = 0.35, P = 0.044;
SN: r = 0.47, P = 0.0073; IN: r = 0.44, P = 0.012). Repres-
entative examples are shown in Fig. 4. In contrast to Fig. 1, a
clear worsening over stages is observed. Correlation analyses
between the motor UPDRS and achromatic performance
(luminance modulation) confirmed these results (Foveal
Index Measure: r = 0.49, P = 0.0019; Peripheral Index
Measure: r = 0.43, P = 0.0061). Thresholds in the SN visual
quadrant were the most significantly correlated with the
motor UPDRS: r = 0.46, P = 0.0032, ST: r = 0.35, P = 0.03;
IT: r = 0.35, P = 0.025; IN: r = 0.39, P = 0.014. The effect
of medication in test performance (using non-parametric
statistics) showed no significant differences.
It is important to test whether or not our measurements
of damage within magno-, parvo- and koniocellular pathways
in Parkinson’s disease are indeed independent, as is to be
expected if parallel pathways were being separately explored.
The results of this analysis showed that there was no evidence
of an association between measurements of chromatic and
achromatic contrast sensitivities. Correlation analysis showed
that all of our measurements of chromatic and achromatic
CS were independent (Spearman correlations between
Foveal/Peripheral Index Measures and protan, deutan and
tritan were n.s.; Foveal/Peripheral Index Measures and
ellipses’ length, also n.s.).
Discussion and conclusions
In the present study, we found clear evidence of independent
visual deficits within the parvo, konio and magnocellular
pathways in Parkinson’s disease. Our measures of assessing
sensory performance within the different pathways were stat-
istically independent (see Methods), which allows for
unbiased comparison of damage within these pathways.
Such statistical independence was not surprising, given the
considerable amount of evidence that our spatiotemporal
method isolates theM/Y pathway (Purpura et al., 1988, 1990).
In any case, the value of our FD stimuli in assessing retino-
topic magnocellular damage as early as at the retina stage has
already been demonstrated in glaucoma (Maddess et al., 1992,
1999; Johnson et al., 1997; Landers et al., 2000; Trible et al.,
2000; Paczka et al., 2001; Shabana et al., 2003). There is also
direct neurophysiological evidence that these stimuli differ-
entially activate magno neurons (Derrington and Lennie,
1984; Merigan and Maunsell, 1993; Lee, 1996). Likewise,
the strategy used in the pure chromatic contrast modulation
tests allows isolating two distinct colour pathways (Regan
et al., 1994; Pearson et al., 2001; Shevell, 2003). It could be
argued that the absence of correlations between chromatic
and luminance modulation measures might be due to
involvement of different retinal areas. However, correlations
remained close to zero even when spatially averaged (global)
measures were used.
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We have observed involvement of chromatic pathways in
Parkinson’s disease even in some recently diagnosed patients.
Surprisingly, predominant effects were found in measures of
the function of the parvocellular pathway. Koniocellular
involvement found in earlier reports may have been overes-
timated due to ageing effects. This may help explain the results
of Birch (Birch et al., 1998), who concluded that clinical tests
for tritan colour deficiency are unlikely to be helpful in iden-
tifying Parkinson’s disease (but see Haug et al., 1995). These
observations are also compatible with the notion that ageing
processes within ocular structures, such as the retina and the
lens, are more prone to affect tritan measures (Wyszecki and
Stiles, 1982; Pokorny et al., 1987; for reviews seeWerner et al.,
1990; Packer and Williams, 2003). Thus, it is important
Fig. 4 Top inset: basic scheme of tested locations of the sinusoidal grating stimulus which induces a magnocellular-isolating frequency-
doubling (FD) illusion (for details see Methods). Lower panels: representative examples of achromatic CS plots (left eye), where darker grey
regions correspond to higher (worse) contrast thresholds (%). Grey level scale bar depicts % contrast thresholds. Note the clear-cut
deterioration across stages.
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to ensure that neither significant lens opacification is present
nor age-related senile changes are observed in fundus
examination, even when groups are age-matched. Our careful
ophthalmological examinations allowed exclusion of these
and other confounding factors such as increased intraocular
pressure; even control subjects underwent the same type of
careful assessment, with exactly the same exclusion criteria.
All tests were measuring multiple colour axes randomly
(multiple interleaved staircases), and since there was no
fixed order there is no possibility that an attentional bias
could have occurred during the tests.
We suggest that assessment of parvocellular pathways
may be more promising than the traditional koniocellular
assessment strategy, even when chromatic discrimination
ellipses show a tritan tilt. One should, however, note that
some Parkinson’s disease patients may have entirely normal
thresholds. Some studies have indeed pointed out that only a
subset of Parkinson’s disease patients (as low as 22.7%) may
show chromatic deficits (Birch et al., 1998; Regan et al., 1998).
Magnocellular thresholds, as measured using a tailored
achromatic CS task, were significantly higher in Parkinson’s
disease both in foveal and peripheral locations. The spati-
otemporal profile of the stimulus used in the task was optim-
ized to independently isolate the M/Y pathway. The high CS
at high temporal frequencies, observed under our M-test
conditions (see also Mestre, 1990b), is a hallmark of magno-
cellular isolation (Lee, 1996).
In contrast with chromatic tasks, performance under
luminance modulation conditions showed a significant deter-
ioration with stage. Future studies should investigate the
role of intragroup ageing effects (since normal controls did
not show any effect of age on magnocellular performance).
In any case, our findings imply a significant involvement
of early (probably in the retina) magnocellular maps in
Parkinson’s disease (for details on their topography see
Curcio et al., 1990; Silveira and Perry, 1991; Yamada et al.,
2001).
The significant change in foveal CS that we have found
is consistent with evidence suggesting that dopaminergic
innervation around the fovea is reduced in Parkinson’s dis-
ease patients (Nguyen-Legros, 1988). An electrophysiological
study from Ikeda et al. (1994), in newly diagnosed Parkinson’s
disease patients (in Stage 1), suggests that the retina is a likely
source of impairment (as revealed by early changes in EOG).
Follow-up of these patients revealed subsequent (in Stage 2)
global ERG abnormalities. We do also believe that the found
deficits are likely to be at least partially located in the retina. In
the subset of 21 patients in which both eyes were tested using
the magno isolating stimuli, we observed a pattern of asym-
metry very similar to the one typically observed in glaucoma
(see references above) which represents evidence for involve-
ment at the level of the retina, as previously suggested by
Harnois and di Paolo (1990). Retinal impairment could,
in turn, lead to specific metabolic occipital glucose hypo-
metabolism (Bohnen et al., 1999). The main source of the
retinal deficit is probably at the ganglion cell level which is
consistent with the PERG (pattern electroretinogram) liter-
ature (Tagliati et al., 1996) in Parkinson’s disease, and the fact
that PERG responses predominantly reflect the activity of
retinal ganglion cells (Fiorentini et al., 1981; Harrison et al.,
1987; Bach, 2001). This is also consistent with recent evidence
showing retinal nerve fibre layer thinning in Parkinson disease
(Inzelberg et al., 2004). The work of Bodis-Wollner and
Tzelepi (1998) is in this sense seminal, because it discusses
the PERG spatial contrast response function in terms of
the envelope output of retinal ganglion cells or the average
or ‘equivalent’ retinal ganglion cell. It also postulates
the existence of a ‘push-pull’ mechanism related to two
dopamine-sensitive pathways with different weights for two
classes of ganglion cells. One uses D1 receptors and is prim-
arily affecting the ‘surround’ organization of ganglion cells
with large centres, while the other uses D2 post-synaptic
receptors and contributes to ‘centre’ response amplification
of ganglion cells with smaller centres. A preganglionic mech-
anism is unlikely to contribute to the chromatic data as well
because experiments performed under blue cone adaptation
conditions showed that although ellipses are larger than for
control subjects, this increase is proportional to the baseline
impairment.
Since we could show that our quantitative measures of
chromatic and achromatic CS are independent, and differ-
ently related to stage, future studies should address the role of
medication in sensory impairment in early disease stages
Fig. 5 (A) Both Foveal Index and Peripheral Index Measures
(which average the 16 peripheral locations) are significantly
different between control and Parkinson’s disease groups.
(B) Achromatic CS detection thresholds compared across visual
field quadrants for each group of subjects. ST, superior temporal;
SN, superior nasal; IN, inferior nasal; IT, inferior temporal
quadrant. Error bars correspond to 1 SE.
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(Buttner et al., 1994, 2000; for a review see Bodis-Wollner,
1990, 2002; Mestre et al., 1990a, b, 1996). Most of our patients
were in early stages, and some were even newly diagnosed
without any medication (similarly to the study of Ikeda et al.,
1994). We have seen no significant difference between the
treated versus the untreated ‘de novo’ patients, although aver-
age scores were better for the treated group. These results are
consistent with the idea that the dopaminergic treatment may
partially compensate (Buttner et al., 1994) the progression of
visual impairment.
Some studies of colour discrimination and CS in
Parkinson’s disease have analysed the influence of disease
progression on performance (Price et al., 1992; Buttner
et al., 1994). Diederich et al. (2002) have tested Parkinson’s
disease patients with relatively normal visual acuity
(Snellen fraction >0.6 in the best eye) and have used classical
procedures, which do not allow for the extraction of
patient reliability indexes (e.g. percent false positive and
negative measures). These tests (Lanthony D15 test,
Farnsworth–Munsell 100-Hue test, monocular and binocular
Pelli–Robson test and the Vistech tables) have been widely
used before to study CS deficits in Parkinson’s disease (Harris,
1998; Pieri et al., 2000; Diederich et al., 2002; for a review see
Bodis-Wollner, 2003). Some have further suggested inde-
pendent impairment of both colour and contrast discrimina-
tion (Pieri et al., 2000). However, these methods are only
semi-quantitative, owing to low score reproducibility (Roth
and Lanthony, 1999). Recent quantitative studies of chro-
matic function were able to determine reliability indexes
for every patient, and proved to have excellent reproducibility
in detection of early visual damage (Regan et al., 1994;
Castelo-Branco et al., 2004; Campos et al., 2005; for other
previous quantitative achromatic CS studies see Bodis-
Wollner et al., 1987; Mestre et al., 1990a, b). We suggest
that future studies should use random psychophysical stair-
cases due to their improved sensitivity and robustness against
cognitive confounding factors.
Taken together, our findings suggest a differential and inde-
pendent involvement of parvo- (red–green), konio- (blue–
yellow) and magnocellular visual pathways in Parkinson’s
disease. This indicates that distinct mechanisms, possibly
related to different patterns of dopaminergic modulation
(Bodis-Wollner and Tzelepi, 1998; Buttner et al., 2000),
contribute to sensory impairment in Parkinson’s disease.
Future studies should address the effect of medication in
these different types of deficit, in distinct disease stages.
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